Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Takaaki Oba [verfasserIn] Mark D. Long [verfasserIn] Tibor Keler [verfasserIn] Henry C. Marsh [verfasserIn] Hans Minderman [verfasserIn] Scott I. Abrams [verfasserIn] Song Liu [verfasserIn] Fumito Ito [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Übergeordnetes Werk:	In: Nature Communications - Nature Portfolio, 2016, 11(2020), 1, Seite 20
Übergeordnetes Werk:	volume:11 ; year:2020 ; number:1 ; pages:20

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1038/s41467-020-19192-z

Katalog-ID:	DOAJ074715895

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ074715895
003	DE-627
005	20230502124428.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1038/s41467-020-19192-z \|2 doi
035			\|a (DE-627)DOAJ074715895
035			\|a (DE-599)DOAJ624c24703da040c89811cce847e51d8c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Takaaki Oba \|e verfasserin \|4 aut
245	1	0	\|a Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.
653		0	\|a Science
653		0	\|a Q
700	0		\|a Mark D. Long \|e verfasserin \|4 aut
700	0		\|a Tibor Keler \|e verfasserin \|4 aut
700	0		\|a Henry C. Marsh \|e verfasserin \|4 aut
700	0		\|a Hans Minderman \|e verfasserin \|4 aut
700	0		\|a Scott I. Abrams \|e verfasserin \|4 aut
700	0		\|a Song Liu \|e verfasserin \|4 aut
700	0		\|a Fumito Ito \|e verfasserin \|4 aut
773	0	8	\|i In \|t Nature Communications \|d Nature Portfolio, 2016 \|g 11(2020), 1, Seite 20 \|w (DE-627)626457688 \|w (DE-600)2553671-0 \|x 20411723 \|7 nnns
773	1	8	\|g volume:11 \|g year:2020 \|g number:1 \|g pages:20
856	4	0	\|u https://doi.org/10.1038/s41467-020-19192-z \|z kostenfrei
856	4	0	\|u https://doaj.org/article/624c24703da040c89811cce847e51d8c \|z kostenfrei
856	4	0	\|u https://doi.org/10.1038/s41467-020-19192-z \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2041-1723 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_211
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 11 \|j 2020 \|e 1 \|h 20

Indexfelder

author_variant	t o to m d l mdl t k tk h c m hcm h m hm s i a sia s l sl f i fi
matchkey_str	article:20411723:2020----::vroigrmradcurdeitneonid1hrpbidcinnat
hierarchy_sort_str	2020
publishDate	2020
allfields	10.1038/s41467-020-19192-z doi (DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c DE-627 ger DE-627 rakwb eng Takaaki Oba verfasserin aut Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade. Science Q Mark D. Long verfasserin aut Tibor Keler verfasserin aut Henry C. Marsh verfasserin aut Hans Minderman verfasserin aut Scott I. Abrams verfasserin aut Song Liu verfasserin aut Fumito Ito verfasserin aut In Nature Communications Nature Portfolio, 2016 11(2020), 1, Seite 20 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:11 year:2020 number:1 pages:20 https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/article/624c24703da040c89811cce847e51d8c kostenfrei https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 20
spelling	10.1038/s41467-020-19192-z doi (DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c DE-627 ger DE-627 rakwb eng Takaaki Oba verfasserin aut Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade. Science Q Mark D. Long verfasserin aut Tibor Keler verfasserin aut Henry C. Marsh verfasserin aut Hans Minderman verfasserin aut Scott I. Abrams verfasserin aut Song Liu verfasserin aut Fumito Ito verfasserin aut In Nature Communications Nature Portfolio, 2016 11(2020), 1, Seite 20 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:11 year:2020 number:1 pages:20 https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/article/624c24703da040c89811cce847e51d8c kostenfrei https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 20
allfields_unstemmed	10.1038/s41467-020-19192-z doi (DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c DE-627 ger DE-627 rakwb eng Takaaki Oba verfasserin aut Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade. Science Q Mark D. Long verfasserin aut Tibor Keler verfasserin aut Henry C. Marsh verfasserin aut Hans Minderman verfasserin aut Scott I. Abrams verfasserin aut Song Liu verfasserin aut Fumito Ito verfasserin aut In Nature Communications Nature Portfolio, 2016 11(2020), 1, Seite 20 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:11 year:2020 number:1 pages:20 https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/article/624c24703da040c89811cce847e51d8c kostenfrei https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 20
allfieldsGer	10.1038/s41467-020-19192-z doi (DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c DE-627 ger DE-627 rakwb eng Takaaki Oba verfasserin aut Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade. Science Q Mark D. Long verfasserin aut Tibor Keler verfasserin aut Henry C. Marsh verfasserin aut Hans Minderman verfasserin aut Scott I. Abrams verfasserin aut Song Liu verfasserin aut Fumito Ito verfasserin aut In Nature Communications Nature Portfolio, 2016 11(2020), 1, Seite 20 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:11 year:2020 number:1 pages:20 https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/article/624c24703da040c89811cce847e51d8c kostenfrei https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 20
allfieldsSound	10.1038/s41467-020-19192-z doi (DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c DE-627 ger DE-627 rakwb eng Takaaki Oba verfasserin aut Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade. Science Q Mark D. Long verfasserin aut Tibor Keler verfasserin aut Henry C. Marsh verfasserin aut Hans Minderman verfasserin aut Scott I. Abrams verfasserin aut Song Liu verfasserin aut Fumito Ito verfasserin aut In Nature Communications Nature Portfolio, 2016 11(2020), 1, Seite 20 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:11 year:2020 number:1 pages:20 https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/article/624c24703da040c89811cce847e51d8c kostenfrei https://doi.org/10.1038/s41467-020-19192-z kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2020 1 20
language	English
source	In Nature Communications 11(2020), 1, Seite 20 volume:11 year:2020 number:1 pages:20
sourceStr	In Nature Communications 11(2020), 1, Seite 20 volume:11 year:2020 number:1 pages:20
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Science Q
isfreeaccess_bool	true
container_title	Nature Communications
authorswithroles_txt_mv	Takaaki Oba @@aut@@ Mark D. Long @@aut@@ Tibor Keler @@aut@@ Henry C. Marsh @@aut@@ Hans Minderman @@aut@@ Scott I. Abrams @@aut@@ Song Liu @@aut@@ Fumito Ito @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	626457688
id	DOAJ074715895
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ074715895</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502124428.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1038/s41467-020-19192-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ074715895</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ624c24703da040c89811cce847e51d8c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takaaki Oba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mark D. Long</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tibor Keler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry C. Marsh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hans Minderman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scott I. Abrams</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Song Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fumito Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nature Communications</subfield><subfield code="d">Nature Portfolio, 2016</subfield><subfield code="g">11(2020), 1, Seite 20</subfield><subfield code="w">(DE-627)626457688</subfield><subfield code="w">(DE-600)2553671-0</subfield><subfield code="x">20411723</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:20</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-020-19192-z</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/624c24703da040c89811cce847e51d8c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-020-19192-z</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2041-1723</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">20</subfield></datafield></record></collection>
author	Takaaki Oba
spellingShingle	Takaaki Oba misc Science misc Q Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
authorStr	Takaaki Oba
ppnlink_with_tag_str_mv	@@773@@(DE-627)626457688
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	20411723
topic_title	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
topic	misc Science misc Q
topic_unstemmed	misc Science misc Q
topic_browse	misc Science misc Q
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nature Communications
hierarchy_parent_id	626457688
hierarchy_top_title	Nature Communications
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)626457688 (DE-600)2553671-0
title	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
ctrlnum	(DE-627)DOAJ074715895 (DE-599)DOAJ624c24703da040c89811cce847e51d8c
title_full	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
author_sort	Takaaki Oba
journal	Nature Communications
journalStr	Nature Communications
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	20
author_browse	Takaaki Oba Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito
container_volume	11
format_se	Elektronische Aufsätze
author-letter	Takaaki Oba
doi_str_mv	10.1038/s41467-020-19192-z
author2-role	verfasserin
title_sort	overcoming primary and acquired resistance to anti-pd-l1 therapy by induction and activation of tumor-residing cdc1s
title_auth	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
abstract	Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.
abstractGer	Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.
abstract_unstemmed	Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
url	https://doi.org/10.1038/s41467-020-19192-z https://doaj.org/article/624c24703da040c89811cce847e51d8c https://doaj.org/toc/2041-1723
remote_bool	true
author2	Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito
author2Str	Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito
ppnlink	626457688
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1038/s41467-020-19192-z
up_date	2024-07-04T00:17:58.300Z
_version_	1803605537771749376
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ074715895</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502124428.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1038/s41467-020-19192-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ074715895</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ624c24703da040c89811cce847e51d8c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Takaaki Oba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mark D. Long</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tibor Keler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Henry C. Marsh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hans Minderman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Scott I. Abrams</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Song Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fumito Ito</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nature Communications</subfield><subfield code="d">Nature Portfolio, 2016</subfield><subfield code="g">11(2020), 1, Seite 20</subfield><subfield code="w">(DE-627)626457688</subfield><subfield code="w">(DE-600)2553671-0</subfield><subfield code="x">20411723</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:20</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-020-19192-z</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/624c24703da040c89811cce847e51d8c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-020-19192-z</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2041-1723</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">20</subfield></datafield></record></collection>
score	7.399728

Nicht das Richtige dabei?

Schreiben Sie uns!

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?